1 / 15

Chapter 56

Chapter 56. Hematopoietic Agents. Hematopoietic Agents. Process by which blood cells and platelets are produced Types Hematopoietic growth factor Erythropoietic (RBCs) Leukopoietic (WBCs) Thrombopoietic growth factor Oprelvekin (platelets). Erythropoietic Growth Factors.

jasper
Télécharger la présentation

Chapter 56

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chapter 56 Hematopoietic Agents

  2. Hematopoietic Agents • Process by which blood cells and platelets are produced • Types • Hematopoietic growth factor • Erythropoietic (RBCs) • Leukopoietic (WBCs) • Thrombopoietic growth factor • Oprelvekin (platelets)

  3. Erythropoietic Growth Factors • Also known as ESAs (erythropoiesis-stimulating agents) • Adverse effects • Increased risk of deep vein thrombosis (DVT) when used before elective surgery • For patients with cancer • Can shorten time to tumor progression • Reduce overall survival

  4. Epoetin Alfa (Erythropoietin) • Brand names: Epogen, Procrit • Hematopoietic growth factor • Significant effects outside hematopoietic system • Recombinant DNA technology • Uses • Anemia associated with chronic renal failure • Chemotherapy-induced anemia • For HIV-infected patients taking zidovudine • Anemia in patients facing surgery

  5. Epoetin Alfa (Erythropoietin) • Adverse effects • Hypertension • Autoimmune pure red-cell aplasia • Very rare • Cardiovascular events • Cardiac arrest • Hypertension • Heart failure • Thrombotic events (stroke and MI)

  6. Epoetin Alfa (Erythropoietin) • Warnings • Excessive dosage • Cancer patients • Renal failure patients • Preoperative patients • Risk evaluation and mitigation strategy

  7. Epoetin Alfa (Erythropoietin) • Dosage • To minimize risks • Use minimum needed to gradually raise hemoglobin content to eliminate the need for RBC transfusions • Hemoglobin level should not exceed 12 g/dL • Monitoring • Monitor hemoglobin level twice weekly

  8. Longer-Acting Erythropoietins • Darbepoetin alfa (long-acting) • Similar risks and needs for monitoring as epoetin alfa • Patients with hypertension may need increased hypertension medications • Methoxy polyethylene glycol: epoetin beta (very long-acting) • Not marketed in the United States (ongoing patent dispute)

  9. Filgrastim (Neupogen) • Granulocyte colony-stimulating factor • Leukopoietic growth factor • Recombinant DNA technology • Reduces the incidence of severe neutropenia • Produces dose-dependent increase in circulating neutrophils • Reduces the incidence of infection, need for hospitalization, and need for intravenous antibiotics

  10. Filgrastim (Neupogen) • Uses • Cancer • Severe chronic neutropenia • Adverse effects • Bone pain • Leukocytosis

  11. Pegfilgrastim (Granulocyte Colony-Stimulating Factor) • Long-acting • Derivative of filgrastim (Neupogen) • Stimulates myeloid cells to increase production of neutrophils • Adverse effects • Similar to filgrastim • May require opioids for pain relief

  12. Sargramostim (Granulocyte-Macrophage Colony-Stimulating Factor) • Brand name: Leukine • Hematopoietic growth factor • Recombinant DNA technology • Uses • Adjunct to autologous bone marrow transplantation • Treatment of failed bone marrow transplants • Patients with acute myelogenous leukemia (AML) • Adverse effects • Leukocytosis • Thrombocytosis

  13. Oprelvekin (Interleukin-11) • Brand name: Neumega • Thrombopoietic growth factor • Recombinant DNA technology • Uses • Used with myelosuppressive chemotherapy to minimize thrombocytopenia and to decrease the need for platelet transfusions • Adverse effects • Fluid retention • Cardiac dysrhythmias • Effects on the eye • Sudden death

  14. Drugs Related to Hematopoietic Growth Factors • Romiplostim • Eltrombopag • Plerixafor

  15. CAUTION • Epoetin alfa, filgrastim, sargramostim, and oprelvekin stimulate proliferation of bone marrow cells. • USE WITH GREAT CAUTION, if at all, for patients with cancers of bone marrow origin.

More Related